Pressure Injuries and Amniotic Membrane Biologics: An Evidence-Based Protocol

Pressure injuries are among the most resource-intensive wounds in adult care. They stall under the combined effects of persistent ischemia, bacterial colonization, oxidative stress, and an aging cellular microenvironment. For clinicians managing Stage III and IV injuries, the standard toolkit, offloading, debridement, moist wound healing, and infection control, is necessary but often not sufficient to drive closure in a timely window.

Amniotic membrane biologics represent a distinct adjunct. They are not a replacement for offloading or debridement, but when used in a protocol-driven manner they can shift the local wound biology toward repair. This article outlines the rationale, a practical application protocol, and a side-by-side comparison grounded in the verified evidence below.

Why Amniotic Membrane Biologics for Pressure Injuries?

Human amniotic membrane (HAM) has long been studied as a biological wound covering. Its clinical interest in wound care rests on several structural and biological features. Khosravimelal et al. note that HAM possesses cytobiocompatibility, an extracellular matrix (ECM) architecture similar to native skin, growth factors involved in normal wound healing, and antibacterial properties.¹ The membrane also contains epithelial cells, fibroblasts, and mesenchymal stem cells.

The critical manufacturing step is decellularization. Removing cellular material while preserving ECM components reduces immunogenic risk and is intended to improve graft performance.¹ Khosravimelal et al. describe detergent-based, enzyme-based, and mechanical decellularization approaches, emphasizing that the goal is minimal negative impact on ECM integrity.¹

Beyond the scaffold itself, amniotic fluid-derived extracellular vesicles (EVs) demonstrate paracrine potential. Senesi et al. showed that EVs from second-trimester human amniotic fluid carry pro-survival, proliferative, anti-fibrotic, and oxidative-stress-counteracting properties in preclinical models.² For a pressure injury operating in a chronic inflammatory and oxidatively stressed milieu, this paracrine biology is a plausible mechanistic rationale for adjunctive use.

Evidence-Based Application Protocol

Product labels and institutional policies vary, so the following framework should be adapted to the manufacturer's Instructions for Use and your wound center's protocols. The steps reflect a consensus workflow commonly used when integrating amniotic membrane allografts into pressure injury management.

1. Confirm candidacy. Stage III or IV pressure injuries with adequate perfusion, no untreated deep-space infection, and a stable offloading plan are typical candidates. Do not apply over active untreated infection or exposed non-viable structures without surgical consultation.
2. Stage and measure. Document length, width, depth, tunneling, undermining, and wound base. Photography at each visit supports objective tracking.
3. Debride the wound bed. Sharp debridement of non-viable tissue is essential. Amniotic membrane grafts perform best on a vascular, healthy wound bed. Do not place graft on dry eschar or slough without debridement.
4. Control hemostasis and infection. Achieve a clean, bleeding wound bed. Manage bioburden with appropriate topical or systemic therapy per wound culture and clinical signs. Follow OSHA bloodborne pathogen standards and institutional precautions during sharp debridement and graft handling.³
5. Size and prepare the graft. Select a graft that covers the entire wound bed, including undermining and tunneling if appropriate. Allow the graft to hydrate according to the product's Instructions for Use. Orientation is typically stromal side down to the wound bed unless the manufacturer specifies otherwise.
6. Apply and secure. Lay the graft flat without wrinkles. Secure with a non-adherent contact layer and a secondary absorbent dressing. Avoid shear or tension that would displace the graft during offloading.
7. Maintain offloading. Pressure relief is non-negotiable. Use the offloading device and repositioning schedule appropriate to the anatomical location and patient mobility.
8. Re-evaluate on schedule. Reassess at 5 to 7 days initially, then per response. Expect to reapply if the graft has resorbed or if the wound is improving but not closed. Adjust antibiotics, nutrition, and perfusion factors concurrently.

Comparison: Decellularized Amniotic Membrane vs. Standard Care Alone

Clinicians often ask where amniotic membrane products fit relative to advanced dressings, negative pressure therapy, or cellular dermal substitutes. The table below compares the key practical considerations for pressure injury use.

AmnioAMP and Rampart: Product Selection Guidance

NextGen Biologics USA manufactures AmnioAMP and Rampart advanced amniotic membrane wound biologics. The appropriate product depends on wound characteristics, size, location, and physician preference. Both are derived from amniotic membrane and processed to preserve the ECM and associated biological activity.

Selection criteria commonly considered by clinicians include graft thickness, handling characteristics, hydration requirements, and whether the wound presents with undermining or exposed structures. When in doubt, consult the product Instructions for Use and your NextGen Biologics representative for case-specific guidance.

Key Takeaways

• Amniotic membrane biologics provide a decellularized ECM scaffold with growth factor and paracrine signaling potential relevant to chronic wound biology.
• Decellularization is intended to reduce immunogenicity while preserving ECM function.¹
• Amniotic fluid-derived extracellular vesicles have demonstrated anti-oxidative and pro-survival effects in preclinical models.²
• Successful outcomes depend on proper patient selection, sharp debridement, hemostasis, infection control, correct graft application, and rigorous offloading.
• Amniotic membrane grafts are an adjunct to standard care, not a substitute for it.